BillionToOne is working on its qSanger-COVID-19 test, a quantitative COVID-19 assay based on Sanger sequencing that can increase the capacity of diagnostic tests for COVID-19 by hundreds of thousands per day and get around the issue regarding reagent supplies.
Sanger sequencing-based COVID-19 test to be developed by BillionToOne
Sign up for AdvaMed SmartBrief
A daily brief designed specifically for diagnostic product and health information executives.
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.